PRecision gerOMedicinE: Tailored Healthy agEing With Lifestyle, sUpplements and drugS (PROMETHEUS)

What Was Tested

The trial (not phased) is built around NAD+.

As the population ages, the growing prevalence of age-related diseases is creating substantial challenges for healthcare systems worldwide.

It had two arms (groups): 1 Fundamental intervention (experimental) and 2 Augmented intervention (experimental).

Participants receive a multimodal lifestyle intervention including sleep optimization, dietary counseling, supervised exercise with an exergaming component, motivational interviewing, and baseline nutritional supplementation.

Participants receive the fundamental intervention and additional personalized supplements based on baseline muscle mass, cardiorespiratory fitness, and cognitive performance, with possible mid-study adjustment.

The registry classes the interventions as behavioral, dietary supplement and other.

More on the Plan

The criteria for inclusion concentrate on individuals scoring below the 75th percentile for normative values in VO₂peak and cognitive performance.

This demographic presents an optimal opportunity for interventions aimed at prolonging healthspan and postponing functional decline.

Who Took Part

Enrollment: 20 planned participants were the target.

It was open to people of any sex aged from 50 years up to 80 years.

Healthy volunteers could join, not only people with the condition.

Examples of who could join: Age 50-80 years (both male and female). Relatively healthy and in stable health condition. Not engaged in regular resistance or aerobic training in the past 12 months (i.e., untrained). VO₂peak below the 75th percentile for age- and sex-specific norms. Cognitive performance below 75th percentile on the NIH Toolbox Cognitive Function Battery.

The full record lists 10 inclusion and 9 exclusion criteria; among the exclusions: history of major cardiovascular disease (e.g., coronary artery disease, heart failure, stroke); more than two unstable chronic conditions (e.g., hypertension, diabetes, osteoarthritis, copd); known allergies to soy, shellfish/seaweed, mushrooms, or supplement ingredients.

How the Study Was Run

It was run as a non-randomized, sequential and open-label study.

Everyone knew when NAD+ was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

It started in 2025-09-29 with completion listed for 2026-02-23.

It ran at 1 site in Singapore.

Its stated primary purpose is health services research.

What Was Measured

The main thing measured (primary outcome): Change from baseline in cardiorespiratory fitness (VO₂peak) (time frame: Baseline, Week 4, and Week 8). Change from baseline in muscle strength (one-repetition maximum (1RM)) (time frame: Baseline, Week 4, and Week 8). Change from baseline in muscle mass (Ultrasound imaging) (time frame: Baseline, Week 4, and Week 8).

It also tracked 20 secondary outcomes, for example Change from Baseline in Circulating Cytokines, Chemokines, and Growth Factors, Change from baseline in advanced glycation end-products, Change from baseline in methylation levels, Change from baseline in blood multi-omics profiles, Change from baseline in gut microbiome composition and fuctional capacity and Change from Baseline in Body Composition (Fat and Lean Mass).

What This Means in Plain Language

Put simply, this is a not phased, non-randomized trial of NAD+ in 20 people.

Its size is small, so on its own it can only give an early look.

It is still recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the NAD+ compound page, all human trials.